3-(4-chlorophenyl)-1-phenylbutan-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-(4-chlorophenyl)-1-phenylbutan-1-one
• 化学式: C₁₆H₁₅ClO
• 分子量: 258.748
• InChiKey: QMSIENXDRCHRAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  ethyl 3-(4-chlorophenyl)-2-butenoate 在 4-hydroxy-2,6-di(naphthalen-2-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide 、 异丙基氯化镁 、 频那醇硼烷 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 生成 3-(4-chlorophenyl)-1-phenylbutan-1-one
  参考文献：
  名称：

  使用BINOL衍生的硼磷酸盐催化反查尔酮衍生物的不对称转移氢化反应。

  摘要：

  在这项工作中，已经研究了手性磷酸催化反式查耳酮的不对称还原。利用硼烷作为氢化物来源，实现了反式查尔酮衍生物的碳-碳双键的BINOL衍生的硼磷酸盐催化的不对称转移氢化。该方法提供了在温和条件下以高收率和高对映选择性获得手性二氢氢醌衍生物的简便方法。

  DOI：

  10.1021/acs.orglett.0c02042

文献信息

• Visible-Light-Promoted Photocatalyst-Free Hydroacylation and Diacylation of Alkenes Tuned by NiCl₂·DME
  作者：Xinxin Zhao、Bing Li、Wujiong Xia

  DOI：10.1021/acs.orglett.9b04595

  日期：2020.2.7

  4-dihydropyridines via an acyl radical addition and hydrogen atom transfer pathway under photocatalyst-free conditions. The efficiency was highlighted by wide substrate scope, good to high yields, successful scale-up experiments, and expedient preparation of highly functionalized ketone derivatives. In addition, this protocol allows for the synthesis of 1,4-dicarbonyl compounds through alkene diacylation in the presence

  在这里，我们描述了一种可见光促进的加氢酰化策略，该策略有助于在无光催化剂的条件下，通过酰基加成和氢原子转移途径，从烯烃和4-酰基-1,4-二氢吡啶制备酮。广泛的底物范围，良好至高收率，成功的按比例放大实验以及方便地制备高度官能化的酮衍生物等突出了效率。另外，该方案允许在NiCl2·DME存在下通过烯烃二酰化反应合成1,4-二羰基化合物。
• Catalytic Carbocation Generation Enabled by the Mesolytic Cleavage of Alkoxyamine Radical Cations
  作者：Qilei Zhu、Emily C. Gentry、Robert R. Knowles

  DOI：10.1002/anie.201604619

  日期：2016.8.16

  weak C−O bond. Spontaneous scission results in the formation of the stable nitroxyl radical TEMPO. as well as a reactive carbocation intermediate that can be intercepted by a wide range of nucleophiles. Notably, this process occurs under neutral conditions and at comparatively mild potentials, enabling catalytic cation generation in the presence of both acid sensitive and easily oxidized nucleophilic

  描述了一种新的催化方法，该方法通过烷氧基胺自由基阳离子的介观裂解来获得碳正离子中间体。在此过程中，激发态氧化剂与TEMPO衍生的烷氧基胺底物之间的电子转移会产生带有非常弱的C-O键的自由基阳离子。自发断裂导致形成稳定的硝基自由基TEMPO 。以及可被多种亲核试剂截获的反应性碳正离子中间体。值得注意的是，该过程在中性条件下和相对温和的电势下发生，从而在酸敏感和易氧化的亲核分子同时存在的情况下能够产生催化阳离子。
• Ketone Synthesis by Direct, Orthogonal Chemoselective Hydroacylation of Alkenes with Amides: Use of Alkenes as Surrogates of Alkyl Carbanions
  作者：Hui Geng、Pei‐Qiang Huang

  DOI：10.1002/cjoc.201900252

  日期：2019.8

  and direct transformation of carboxamides are two exciting areas that have attracted considerable attention in recent years. We report herein that secondary amides, the least reactive derivatives of carbonyl compounds, upon activated with triflic anhydride, can serve as effective hydroacylating reagents in partner with alkenes to yield ketones at ambient temperature. The method was applied to the one‐step

  烯烃的直接官能化和羧酰胺的直接转化是近年来令人瞩目的两个令人兴奋的领域。我们在此报道，仲酰胺，即羰基化合物的反应性最低的衍生物，在用三氟甲磺酸酐活化后，可以与烯烃一起作为有效的氢酰化试剂，在环境温度下产生酮。该方法已用于外消旋二氢芳基羟色酮的一步合成。在这种方法中，烯烃用作有机金属试剂的替代物，从而可以进行正交的化学选择性反应。许多烯烃（如camp烯和降冰片烯）的现成性允许一步合成酮，而传统方法则需要几个步骤。
• [EN] ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE ALPHA-AMINO BORONIQUE, INHIBITEURS SÉLECTIFS DE L'IMMUNOPROTÉASOME
  申请人：ARES TRADING SA

  公开号：WO2013092979A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.

  本发明提供了化合物的公式（I）作为LMP7的抑制剂，用于治疗自身免疫和炎症性疾病。在公式（I）中，Rb和Rc分别独立地从H或C1-C6-烷基中选择；其中Rb和Rc可以连接形成一个含有它们连接的氧原子的5或6元环；Q表示Ar，Het或环烷基；R1和R2彼此独立地表示H，ORa，Hal，C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Y表示CR 3R4，优选CH2或C(CH3)2；R3，R4彼此独立地表示H或C1-C6-烷基；L表示L1或L2或烷基；n是从0到3选择的整数；L1是Q1-CO-M-，其中Q1是Ar或Het，优选苯基，萘基或吡啶基，可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；L2是Q2-M-，其中Q2是含有1个氮原子和1到3个额外基团的融合双环系统，独立选择自O，S，N或CO，其中至少一个环是芳香环，融合双环系统可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；或Q2是不饱和或芳香的含有1到3个从N，O，S和CO中选择的杂原子的5元环系统，并可选地取代为苯环或吡啶环，其中苯环和吡啶环可选地取代为1到4个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；M是具有1到5个碳原子的线性或支链烷基，其中1或2个H原子可以被ORa或可选地取代为1到5个从Hal，ORa和C1-C6-烷基中独立选择的基团，可选地取代为1到5个从OH和Hal中独立选择的基团；或M表示具有3到7个碳原子的环烷基；或M表示噻唑烷基；Ra是H或C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Ar表示一个6元芳香碳环，可选地与另一个含有5到8个碳原子的碳环饱和、不饱和或芳香环融合；Het表示一个含有1到3个从N，N+O-，O，S，SO和SO2中独立选择的杂原子的5或6元饱和、不饱和或芳香杂环，可选地与另一个含有5到8个原子的饱和、不饱和或芳香环融合，并可选地含有1到3个从N，O和S中选择的杂原子；Hal表示CI，Br，I或F；优选CI或F。
• Palladium-Catalyzed Conjugate Addition of Organosiloxanes to α,β-Unsaturated Carbonyl Compounds and Nitroalkenes
  作者：Scott E. Denmark、Nobuyoshi Amishiro

  DOI：10.1021/jo034763r

  日期：2003.9.1

  aryltrialkoxysilanes to alpha,beta-unsaturated carbonyl compounds (ketones, aldehydes) and nitroalkenes in the presence of SbCl(3), TBAF, AcOH, and a catalytic amount of Pd(OAc)(2), in CH(3)CN at 60 degrees C, provides the corresponding conjugate addition products in moderate to good yields. The addition of equimolar amounts of SbCl(3) and TBAF is necessary for this reaction to proceed smoothly. The arylpalladium

  在SbCl（3），TBAF，AcOH和催化量的Pd（OAc）（2）存在下，在CH（3）中向α，β-不饱和羰基化合物（酮，醛）和硝基烯烃中添加芳基三烷氧基硅烷60℃下的CN以中等至良好的产率提供了相应的缀合物加成产物。为了使该反应顺利进行，必须添加等摩尔量的SbCl（3）和TBAF。由推定的超配位硅化合物通过金属转移生成的芳基钯络合物被认为是催化活性物质。